

MedChem 2007 - New Drugs and Drug Candidates: Recent Achievements in Medicinal Chemistry

Programme

Friday October 26, 2007

- 08:00 Registration**
- 08:50 Introduction**
- 09:00 Nexavar - A Novel Inhibitor of Signal Transduction**
Dr Bernd RIEDL
(BAYER PHARMA, Wuppertal, Germany)
- 09:50 Design, Synthesis and Biological Activity of Therapeutics Targeting the PI3K Pathway**
Dr. Carlos GARCIA-ECHEVERRIA
(NOVARTIS PHARMA, Basel, Switzerland)
- 10:40 Coffee-break & poster session**
- 11:10 Discovery of Sitagliptin and Other Novel DPP4 Inhibitors**
Dr Tesfaye BIFTU
(MERCK, Rahway, United States)
- 12:00 Hit-to-lead studies on Aminopropoxy phenyloxazolines. Discovery of a novel class of potent H3R ligands for the treatment of cognitive dysfunction**
- 12:20 Sandwich lunch & posters**
- 13:40 Dual NK3/NK1 Receptor Antagonism: A Novel Approach for the Treatment of Psychotic Disorders**
Dr Patrick SCHNIDER
(F. HOFFMANN-LA ROCHE, Schlieren, Switzerland)
- 14:30 Isoindolinones as promising inhibitors of the MDM2-P53 protein-protein interaction**
Dr. Eric VALEUR
(MERCK SERONO, Chilly Mazarin, France)
- 14:50 ETHR inhibitors as TB drug boosters: A new strategy to fight tuberculosis**
Prof. Nicolas WILLAND
(UNIVERSITY OF LILLE, Lille, France)
- 15:10 Coffee-break & poster session**
- 15:40 Discovery of R256918 a Gut-Selective MTP Inhibitor to Treat Obesity**
Dr Lieven MEERPOEL
(JOHNSON & JOHNSON PRD, Belgium)
- 16:30 Inhibitors of Thrombin Activatable Fibrinolysis Inhibitor (TAFIa)**
Dr Mark BUNNAGE
(PFIZER, Boston, United States)
- 17:20 Closing remarks**